查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1863567

肺癌基因組檢測市場：2025-2032年全球預測（按技術、檢測類型、應用和最終用戶分類）

Lung Cancer Genomic Testing Market by Technology, Test Type, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，肺癌基因組檢測市場將成長至 20.7 億美元，複合年成長率為 8.56%。

關鍵市場統計數據
基準年 2024 10.7億美元
預計年份：2025年 11.6億美元
預測年份 2032 20.7億美元
複合年成長率 (%) 8.56%

技術進步和臨床整合正在重新定義肺癌基因組檢測，並塑造治療路徑。

肺癌基因組檢測目前處於臨床緊迫性和技術能力的交匯點，正在重塑診斷、治療決策和轉化研究。隨著分子資訊日益成為標靶治療治療和免疫療法適用性的決定因素，臨床醫生和實驗室正在積極採用基因組檢測，並從組織學驅動的治療路徑轉向基於精準醫學的治療路徑。這促成了以往各自獨立的學科（病理學、分子生物學、生物資訊學和臨床腫瘤學）的融合，從而提供整合的治療路徑，縮短標靶治療時間，並實現更精準的患者分層。

此外，檢測格局正從單基因檢測發展到多基因panel和全面的基因組分析，從而能夠捕捉可操作的突變、拷貝數變異和複雜的基因組特徵。與基於組織的檢測方法相輔相成，微創替代方法（例如血液檢測）正在加速診斷流程，並改善患者持續監測的可及性。同時，監管政策的明確性、支付方的參與以及臨床指南的更新也日益趨於一致，基因組檢測正成為許多腫瘤治療網路中標準治療的核心組成部分。這些趨勢正在塑造一種新的商業環境，其中技術差異化、證據生成和營運韌性將決定哪些機構主導下一波臨床和商業性應用浪潮。

定序、液態生物檢體和數位生物資訊學的進步正在融合，迅速改變肺癌診療的診斷流程和病患管理方式。

肺癌基因組檢測領域正經歷多項變革，主要得益於檢測技術、數據分析和診療模式的進步。其中最顯著的是，次世代定序已從高成本、以研究為導向的工作流程，發展成為更有效率、經臨床檢驗的平台，支援全EXOME和全基因組定序以及標靶定序panel等多種覆蓋方式。這項進步使臨床醫生能夠檢測罕見突變和全面的基因組特徵，同時也使實驗室能夠最佳化檢測通量和縮短結果週轉時間。

同時，涵蓋循環性腫瘤細胞和循環腫瘤DNA的液態生物檢體調查方法正從輔助工具轉變為診斷和監測策略的重要組成部分。這些檢測方法提供了一種微創手段，可以捕捉腫瘤異質性，並監測治療反應和新抗藥性的出現。此外，即時聚合酵素鏈鎖反應（PCR）和螢光雜合反應（FISH）在特異性和快速生物標記檢測方面仍然發揮關鍵作用，尤其是在監管和支付框架支持成熟方法的情況下。

同時，數位醫療和人工智慧驅動的生物資訊學日益成熟，能夠支持自動化突變檢測、臨床註釋和決策支持，從而減少解讀瓶頸，並實現跨不同臨床環境的可擴展報告。監管機構正在調整伴隨診斷和複雜基因組檢測的指導方針，而支付方則在加強對臨床效用和基於價值的報銷路徑的評估。這些變化共同建構了一個更整合、數據豐富的生態系統，重視證據產生、互通性和營運靈活性。

近期關稅引發的供應鏈壓力如何重塑基因組診斷的採購、生產策略和商業性模式

近期各國政策制定者對關稅的調整，使得診斷生態系統更重視供應鏈韌性與籌資策略。由於基因組檢測依賴全球供應鏈來獲取試劑、定序設備、塑膠耗材和專用微流體組件，關稅導致的成本增加將波及實驗室運作、試劑採購週期以及資本設備購置決策。因此，實驗室和診斷服務提供者必須重新評估供應商合約、庫存策略和資本投資計劃，以確保服務的連續性和可接受的檢測結果週轉時間。

為此，多方相關人員正在探索替代採購管道和本地製造夥伴關係，以降低進口關稅和運輸波動帶來的風險。採購團隊正在協商長期供應協議，並優先選擇生產地點多元化的供應商，以減少單一來源風險。同時，診斷試劑開發商正在加快研發可減少試劑用量並允許替換關稅敏感成分的檢測方案，從而減輕進口關稅對其營運的影響。

從臨床角度來看，持續的成本壓力可能會延緩某些醫療機構採用昂貴且全面的檢測方法，除非有支付方的醫保覆蓋或打包合約來抵銷成本。這促使實驗室和設備製造商加大對衛生經濟學證據和真實世界效用研究的投入，以證明成本效益並支持基於價值的合約的製定。整體而言，關稅壓力是推動策略轉型、供應鏈多元化、在地化生產和商業性永續的檢測設計的重要催化劑。

針對特定細分市場的洞察，展示了技術選擇、檢體模式、臨床應用和最終用戶能力如何相互作用，從而決定採用路徑和價值提案。

詳細的細分分析揭示了不同技術、檢測類型、應用領域和最終用戶類別所呈現的截然不同的應用模式，從而影響市場機會和投資重點。在技​​術方面，檢測方法多種多樣，從螢光原位雜合反應和微陣列平台到即時聚合酵素鏈鎖反應和桑格定序，不一而足。然而，次世代定序（NGS）已成為一項核心技術，其配置多種多樣，包括用於精準檢測可操作突變的靶向定序panel、用於全面分析編碼區的全EXOME定序以及用於最廣泛突變檢測和結構解析的全基因測序。每種配置在靈敏度、覆蓋範圍、週轉時間和結果解讀複雜度方面各有優劣。

從檢測類型來看，此領域可分為液態生物檢體和組織切片檢查兩種方式。液態生物檢體包括循環性腫瘤細胞(CTC) 和循環腫瘤 DNA (ctDNA) 檢測，具有微創取樣和連續監測的極佳可行性。組織切片檢查對於組織病理學評估至關重要，包括細針穿刺以及用於免疫組織化學和分子檢測的傳統組織切片。這兩種取樣技術在診斷流程中通常發揮互補作用，最佳檢測順序取決於特定的診斷管理方案。

在應用方面，檢測可用作伴隨診斷，直接指導治療方案的選擇；用作預測性檢測，預測治療反應；用作預後檢測，實現預後預測；以及用作治療監測，檢測抗藥性和復發。檢測的普及程度取決於臨床環境、實證依據和支付方的合作情況。最終用戶包括推動檢測方法檢驗和轉化研究的學術和研究機構、提供大規模臨床檢測並管理患者流程的醫院和診斷實驗室，以及依賴強大的基因組表徵來支持藥物發現、伴隨診斷合作和患者選擇策略的製藥和生物技術公司。這些群體之間的相互作用凸顯了客製化價值提案涵蓋了從高通量臨床檢測服務到用於藥物發現的特定轉化平台等各個方面。

影響技術採納、報銷參與和策略合作的區域採納趨勢和基礎設施因素

區域趨勢對技術應用、監管協調和商業策略產生了重大影響，美洲、歐洲、中東和非洲以及亞太地區呈現出截然不同的模式。在美洲，由學術機構、綜合醫療系統和診斷創新者組成的強大生態系統推動了先進基因組分析和液態生物檢體檢測的早期臨床應用。該地區的報銷框架和大規模臨床研究支持將伴隨診斷整合到治療路徑中，領先的實驗室和商業合作夥伴也持續投資於平台擴充性和臨床檢驗計畫。

歐洲、中東和非洲地區的情況更為複雜，多個國家法律規範較強，但醫療資源取得和基礎設施水準卻參差不齊。歐洲各國正努力協調伴隨診斷的臨床證據和監管要求，合作研究網路也促進了多中心合作，以應對臨床效用的挑戰。然而，在中東和北非地區的某些區域，由於實驗室能力和報銷障礙，醫療資源取得仍然有限，因此需要重點發展區域卓越中心和公私合營，以擴大先進檢測服務的覆蓋範圍。

亞太地區臨床和生產能力的快速擴張引人注目，但其支付方格局呈現出多元化的特徵。在當地診斷產業蓬勃發展和基因組學領域巨額投資的推動下，多個市場對定序平台和液態生物檢體檢測的採用率均顯著提高。然而，不同地區的採用率存在差異，一些具有戰略意義的企業通常會將集中式高複雜度檢測中心與分散式檢體採集和數位化報告系統相結合，以克服地域和資源方面的限制。這些區域差異凸顯了打入市場策略的必要性，這些策略必須充分考慮當地的監管流程、報銷機制和醫療基礎設施。

定序儀製造商、試劑供應商、診斷實驗室和生物製藥合作夥伴如何協調策略，以實現臨床應用和商業性差異化

肺癌基因組檢測價值鏈的競爭主要集中在以下幾類公司之間：提供定序平台、檢測試劑、綜合診斷服務和臨床解讀解決方案的公司，以及將檢測與治療方案結合的臨床實驗室和診斷開發公司。領先的儀器供應商正致力於推進先進的平台藍圖，重點關注通量、運行成本和整合分析；而試劑和試劑套件供應商則在穩健性、批間一致性和臨床檢驗方案方面展開競爭，這些方案能夠簡化監管申報和實驗室認證流程。

診斷實驗室和專科服務提供者正利用垂直整合，提供從檢體接收到臨床報告的端到端服務，這些服務通常輔以專有的生物資訊學流程和精心整理的突變資料庫。製藥和生物技術公司優先考慮能夠提供快速且可重複的基因組表徵的合作夥伴，以幫助篩選臨床試驗的患者並共同開發伴隨診斷。為了拓展檢測產品組合、增強地理覆蓋範圍並加速診斷適應症的上市速度，企業通常會採取合作、分銷協議和定向收購等策略措施。

為了保持競爭力，各機構正加大投入，致力於產生真實世界證據、加強與支付方的合作以及提升與電子健康記錄的互通性，以證明其臨床效用並推動臨床醫生採用。此外，那些提供擴充性的雲端解讀工具並堅持高標準的臨床檢驗的公司，更有利於滿足來自集中式參考實驗室和分散式醫院網路的需求。

為加強供應鏈韌性、加快證據產生以及確保與支付方和合作夥伴協作以實現永續成長，提出切實可行的建議

產業領導者應優先採取一系列切實可行、基於實證的行動，以在應對技術複雜性、政策變化和市場壓力的同時，以實現臨床和商業性價值。首先，應推進供應鏈多元化，並對關稅敏感的試劑和耗材採取本地化生產或第二供應商採購策略，以降低單點故障風險並穩定採購成本。同時，應投資最佳化檢測方法，最大限度地減少試劑用量並簡化工作流程，從而保持獲利能力和韌性。

第二，加速臨床檢驗和真實世界證據項目，以證明其臨床效用和衛生經濟價值。可靠的結果資料集將加強健保談判，並有助於將全面的基因組分析納入標準治療路徑。第三，擴展生物資訊學和人工智慧驅動的解讀能力，以縮短報告週轉時間，提高變異分類的一致性，並實現可擴充性的臨床決策支持，使其能夠與電子健康系統整合。第四，與支付方建立聯繫，探索將醫保報銷與可證實的臨床結果掛鉤的價值基本契約，從而協調各相關人員的獎勵。

第五，我們將與製藥開發商建立策略聯盟，共同開發伴隨診斷試劑，並透過生物標記驅動的篩檢招募臨床實驗參加者。最後，我們將根據不同地區最佳化市場進入策略，使產品聲明和證據包符合當地監管要求，並部署混合模式，將集中式高複雜度檢測與精簡的檢體物流和遠端報告相結合，以擴大市場准入範圍。

採用透明、多方面的調查方法，結合與專家的直接對話和系統的證據審查，以確保得出嚴謹且具有可操作性的研究結果。

本分析所依據的研究採用了一種多方面的方法，結合了初步的定性研究和系統的二手研究，建構了一個穩健的、三角驗證的證據基礎。初步研究包括對臨床實驗室主任、分子病理學家、醫保報銷專家、診斷試劑開發人員和藥物研發負責人進行結構化訪談，並輔以專家專題研討會，以檢驗檢測應用方面的新興趨勢和實際挑戰。這些工作深入分析了實驗室工作流程、採購趨勢以及監管和收費變化對營運的影響。

二次研究包括對監管指導文件、臨床實踐指南、同行評審的關於檢測性能和效用的文獻以及公司披露的戰略重點和產品功能進行嚴格審查。數據綜合優先考慮現有的高品質臨床檢驗研究和真實世界證據。所有發現均經過三角驗證和交叉檢驗，以協調不同的觀點，並確保結論反映的是一致的趨勢，而非孤立的觀察。

在適當情況下，我們採取了分析保障措施，以應對醫療保健和地方政策環境的差異。我們明確闡述了方法論的局限性，尤其是在證據基礎尚未成熟或實踐模式快速變化的情況下。本研究遵循與專家合作和資料處理的倫理標準，以確保定性研究結果的保密性和完整性。

本文簡要概述如何將技術進步與策略性要務結合，從而將基因組檢測轉化為持久的臨床和商業性影響。

先進定序技術、液態生物檢體創新和數位化解讀工具的融合，徹底改變了肺癌基因組檢測的臨床格局。這些發展既帶來了機遇，也帶來了挑戰。機會包括能夠更精準地選擇治療方案、支持適應性臨床試驗以及透過微創檢測進行長期監測。同時，供應鏈管理、證據產生和與支付方的合作等挑戰則需要策略遠見。因此，決策者必須採取整合的觀點，將技術投資、臨床檢驗和商業化路徑有機結合。

有效的應對措施應將營運韌性與實證商業化結合。透過多元化供應來源、投資開發小型化、低成本的檢測方法，並透過嚴謹的研究證明其臨床和經濟價值，相關人員能夠加快技術應用，同時降低政策和市場波動帶來的風險。同時，尊重當地監管標準和醫療基礎設施的區域策略對於將全球潛力轉化為永續的臨床成果至關重要。簡而言之，肺癌精準醫療時代需要產業界、臨床界和監管相關人員的共同努力，才能將技術能力轉化為病患療效的提升。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 利用血液樣本進行早期檢測可治療肺癌突變的新型液態生物檢體技術
  • 整合人工智慧驅動的生物資訊平台，用於快速分析非小細胞肺癌患者的複雜基因組圖譜
  • 實施全面的次世代定序方案，以識別罕見的驅動突變和抗藥性機制。
  • 擴大ALK、ROS1和EGFR突變型非小細胞肺癌標靶治療伴隨診斷的核准
  • 擴大分散式基因組檢測服務，以改善偏遠和醫療服務不足的患者群體獲得檢測的機會。
  • 為進行性肺癌基因組檢測實施報銷框架和基於價值的定價模式

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 肺癌基因組檢測市場（依技術分類）

  • 螢光原位雜合反應
  • 微陣列
  • 次世代定序
    • 標靶定序
    • 全外EXOME定序
    • 全基因測序
  • 即時聚合酵素鏈鎖反應
  • 桑格定序

第9章 肺癌基因組檢測市場（依檢測類型分類）

  • 液態生物檢體
    • 循環性腫瘤細胞
    • 循環腫瘤DNA
  • 組織切片檢查
    • 細針穿刺法
    • 組織切片

第10章 肺癌基因組檢測市場（依應用領域分類）

  • 伴隨診斷
  • 預測性測試
  • 預後測試
  • 治療監測

第11章 肺癌基因組檢測市場（依最終用戶分類）

  • 學術研究機構
  • 醫院和診斷實驗室
  • 製藥和生物技術公司

第12章 肺癌基因組檢測市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 肺癌基因組檢測市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國肺癌基因組檢測市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Illumina, Inc.
    • Thermo Fisher Scientific Inc.
    • F. Hoffmann-La Roche AG
    • QIAGEN NV
    • Guardant Health, Inc.
    • Myriad Genetics, Inc.
    • Natera, Inc.
    • BioMerieux SA
    • NeoGenomics Laboratories, Inc.
    • Foundation Medicine, Inc.
Product Code: MRR-7C31448F0BA8

The Lung Cancer Genomic Testing Market is projected to grow by USD 2.07 billion at a CAGR of 8.56% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.07 billion
Estimated Year [2025] USD 1.16 billion
Forecast Year [2032] USD 2.07 billion
CAGR (%) 8.56%

A comprehensive orientation to how technological advances and clinical integration are redefining lung cancer genomic testing and shaping care pathways

Lung cancer genomic testing now sits at the intersection of clinical urgency and technological capability, reshaping diagnostics, therapeutic decision-making, and translational research. As molecular insights increasingly determine targeted therapies and immunotherapy candidacy, clinicians and laboratories are adopting genomic assays to move from histology-based care to precision-guided treatment pathways. In consequence, previously discrete disciplines-pathology, molecular biology, bioinformatics, and clinical oncology-are converging to deliver integrated care pathways that reduce time to targeted therapy and enable more nuanced patient stratification.

Moreover, the testing landscape is evolving from single-gene assays to multi-gene panels and comprehensive genomic profiling that capture actionable mutations, copy number alterations, and complex genomic signatures. Complementing tissue-based approaches, minimally invasive alternatives such as blood-based testing are accelerating diagnostic workflows and improving patient access to serial monitoring. At the same time, regulatory clarity, payer engagement, and clinical guideline updates are beginning to align, making genomic testing a central component of standard care in many oncology networks. Taken together, these dynamics have created a new operating environment where technological differentiation, evidence generation, and operational resilience determine which organizations lead the next wave of clinical and commercial adoption.

How converging advances in sequencing, liquid biopsy, and digital bioinformatics are rapidly transforming diagnostic pathways and patient management in lung cancer care

The landscape of lung cancer genomic testing is undergoing several transformative shifts driven by advances in assay technology, data analytics, and care delivery models. Most notably, next generation sequencing has evolved from high-cost, research-oriented workflows toward more efficient, clinically validated platforms that support targeted sequencing panels as well as broader coverage through whole exome and whole genome approaches. This progression enables clinicians to detect rare variants and comprehensive genomic signatures while laboratories optimize throughput and turnaround time.

In parallel, liquid biopsy methodologies-encompassing both circulating tumor cells and circulating tumor DNA-are transitioning from complementary tools to integral components of diagnostic and monitoring strategies. These assays offer a less invasive route to capture tumor heterogeneity and to monitor treatment response or emergent resistance. Meanwhile, real time polymerase chain reaction and fluorescence in situ hybridization maintain important roles for specific, rapid biomarker detection, particularly where regulatory or payer frameworks favor established methods.

Concurrently, digital health and AI-driven bioinformatics have matured to support automated variant calling, clinical annotation, and decision support, thereby reducing interpretation bottlenecks and enabling scalable reporting across diverse clinical settings. Regulatory agencies are adapting guidance for companion diagnostics and complex genomic tests, and payers are increasingly evaluating clinical utility and value-based reimbursement pathways. Together, these shifts are creating a more integrated, data-rich ecosystem that rewards evidence generation, interoperability, and operational agility.

How recent tariff-driven supply chain pressures have reshaped procurement, manufacturing strategies, and commercial approaches for genomic diagnostics

Recent tariff adjustments enacted by national policymakers have introduced a renewed emphasis on supply chain resilience and procurement strategy within the diagnostic ecosystem. Because genomic testing relies on a global supply chain for reagents, sequencing instruments, plastic consumables, and specialized microfluidic components, any tariff-driven cost increases reverberate through laboratory operations, reagent procurement cycles, and capital equipment acquisition decisions. As a result, laboratories and diagnostic providers have had to reassess vendor contracts, inventory strategies, and capital planning to preserve service continuity and to maintain acceptable turnaround times.

In response, several stakeholders have explored alternative sourcing and local manufacturing partnerships to mitigate exposure to import levies and shipping volatility. Procurement teams are negotiating longer-term supply agreements and prioritizing suppliers with diversified production footprints to reduce single-source risk. At the same time, diagnostic developers are accelerating work on assay designs that reduce reagent volumes or substitute tariff-sensitive components, thereby lowering the operational impact of import duties.

From a clinical perspective, sustained cost pressure may slow the adoption of more expensive, comprehensive testing in some care settings unless offset by payer coverage or bundled contracting. Consequently, laboratories and device manufacturers are investing in health economic evidence and real-world utility studies to demonstrate cost-effectiveness and inform value-based arrangements. Overall, tariff-driven pressures are catalyzing a strategic reorientation toward supply-chain diversification, localized manufacturing, and commercially sustainable assay design.

Segment-focused insights showing how technology choices, specimen modalities, clinical applications, and end-user capabilities jointly determine adoption pathways and value propositions

A detailed segmentation perspective reveals nuanced adoption patterns across technology, test type, application, and end user categories that are shaping market opportunity and investment priorities. Within the technology dimension, assays range from fluorescence in situ hybridization and microarray platforms to real time polymerase chain reaction and Sanger sequencing; however, next generation sequencing has emerged as a pivotal technology with diverse configurations that include targeted sequencing panels for focused actionable alterations, whole exome sequencing for comprehensive coding-region analysis, and whole genome sequencing for the broadest possible variant detection and structural insight. Each configuration carries distinct trade-offs in sensitivity, breadth of coverage, turnaround time, and interpretive complexity.

Regarding test type, the domain divides between liquid biopsy and tissue biopsy modalities. Liquid biopsy comprises both circulating tumor cells and circulating tumor DNA approaches, offering minimally invasive sampling and superior feasibility for serial monitoring. Tissue biopsy remains essential for histopathologic assessment and includes fine needle aspiration techniques as well as traditional tissue sections used for immunohistochemistry and confirmatory molecular assays. These two sampling paradigms often play complementary roles in the diagnostic pathway, with diagnostic stewardship determining optimal sequencing of tests.

In terms of application, testing supports companion diagnostics that directly guide therapy selection, predictive testing to anticipate treatment response, prognostic testing to inform outcome expectations, and treatment monitoring to detect resistance or recurrence. Adoption intensity varies by clinical setting, evidence base, and payer alignment. Finally, end users encompass academic and research institutes that drive assay validation and translational studies, hospitals and diagnostic laboratories that deliver clinical testing at scale and manage patient workflows, and pharmaceutical and biotechnology companies that rely on robust genomic characterization to support drug development, companion diagnostic partnerships, and patient selection strategies. The interplay among these segments underscores the importance of tailored value propositions, from high-throughput clinical laboratory services to niche translational platforms supporting drug discovery.

Regionally differentiated adoption dynamics and infrastructure considerations that influence technology roll-out, reimbursement engagement, and strategic partnerships

Regional dynamics materially influence technology adoption, regulatory alignment, and commercial strategy, with distinct patterns emerging across the Americas, Europe, Middle East & Africa, and Asia-Pacific regions. In the Americas, a robust ecosystem of academic centers, integrated health systems, and diagnostic innovators has driven early clinical adoption of advanced genomic profiling and liquid biopsy testing. Reimbursement frameworks and large-scale clinical studies in this region have supported the integration of companion diagnostics into therapeutic pathways, while leading laboratories and commercial partners continue to invest in platform scalability and clinical validation programs.

Across Europe, the Middle East and Africa, the landscape is more heterogeneous, characterized by strong regulatory oversight in several countries alongside variability in access and infrastructure. European jurisdictions are increasingly harmonizing regulatory expectations for clinical evidence and companion diagnostics, and collaborative networks are advancing multicenter studies to address clinical utility questions. In contrast, access in some parts of the Middle East and Africa remains constrained by laboratory capacity and reimbursement barriers, prompting a focus on regional centers of excellence and public-private partnerships to extend advanced testing services.

In the Asia-Pacific region, rapid expansion in clinical capacity and manufacturing capabilities is evident alongside diverse payer environments. Several markets demonstrate high adoption rates for both sequencing platforms and liquid biopsy testing, supported by growing local diagnostics industries and targeted investments in genomics. Nevertheless, adoption is uneven, and strategic players often combine centralized high-complexity testing hubs with decentralized sample collection and digital reporting to bridge geographic and resource constraints. These regional distinctions underline the need for market entry strategies that reflect local regulatory processes, reimbursement pathways, and healthcare infrastructure.

How sequencing instrument makers, reagent suppliers, diagnostic laboratories, and biopharma partners are aligning strategies to gain clinical adoption and commercial differentiation

Competitive activity across the lung cancer genomic testing value chain is concentrated among companies that provide sequencing platforms, assay reagents, integrated diagnostic services, and clinical interpretation solutions, as well as among clinical laboratories and diagnostics developers who pair testing with therapeutic programs. Leading instrumentation providers have advanced platform roadmaps focused on throughput, run cost, and integrated analytics, while reagent and kit suppliers compete on robustness, lot-to-lot consistency, and clinical validation packages that simplify regulatory submissions and laboratory accreditation.

Diagnostic laboratories and specialty providers leverage vertical integration, offering end-to-end services from sample accessioning to clinical reporting, often augmenting their offerings with proprietary bioinformatics pipelines and curated variant databases. Pharmaceutical and biotechnology collaborators prioritize partners that can deliver rapid, reproducible genomic characterization to support patient selection in trials and companion diagnostic co-development. Strategic moves such as partnerships, distribution agreements, and targeted acquisitions are common as companies seek to broaden assay portfolios, enhance geographic footprint, and reduce time to market for diagnostic claims.

To remain competitive, organizations increasingly invest in real-world evidence generation, payor engagement, and interoperability with electronic health records to demonstrate clinical utility and to facilitate clinician adoption. Additionally, companies that offer scalable, cloud-enabled interpretation tools and that maintain high standards for clinical validation are best positioned to capture demand from both centralized reference laboratories and decentralized hospital networks.

Action-oriented recommendations for companies to strengthen supply resilience, accelerate evidence generation, and secure payer and partner alignment for sustainable growth

Industry leaders should prioritize a set of pragmatic, evidence-based actions to navigate technological complexity, policy shifts, and market pressures while capturing clinical and commercial value. First, diversify supply chains and pursue localized manufacturing or second-source agreements for tariff-sensitive reagents and consumables to reduce single-point vulnerabilities and to stabilize procurement costs. Parallel to this, invest in assay optimization that minimizes reagent volumes and streamlines workflows to preserve margins and resilience.

Second, accelerate clinical validation and real-world evidence programs that demonstrate clinical utility and health economic value. Robust outcome datasets will strengthen reimbursement negotiations and support placement of comprehensive genomic profiling in standard care pathways. Third, expand capabilities in bioinformatics and AI-driven interpretation to shorten report turnaround time, improve variant classification consistency, and enable scalable clinical decision support that integrates with electronic health systems. Fourth, cultivate payer relationships and explore value-based contracting that ties reimbursement to demonstrable clinical outcomes, thereby aligning incentives across stakeholders.

Fifth, form strategic partnerships with pharmaceutical developers to co-develop companion diagnostics and to secure trial enrollment through biomarker-driven screening. Finally, tailor market access strategies regionally by aligning product claims and evidence packages with local regulatory expectations and by deploying hybrid models that combine centralized high-complexity testing with facilitated sample logistics and remote reporting to broaden access.

A transparent multi-method research approach combining primary expert engagement and systematic evidence review to ensure rigorous and actionable insights

The research underlying this analysis employed a multi-method approach that combined primary qualitative inquiry with systematic secondary intelligence to build a robust and triangulated evidence base. Primary research included structured interviews with clinical laboratory directors, molecular pathologists, reimbursement specialists, diagnostic developers, and pharmaceutical R&D leaders, supplemented by expert panel discussions to validate emerging trends and practical challenges in assay deployment. These engagements provided granular insight into laboratory workflows, procurement dynamics, and the operational impact of regulatory and tariff changes.

Secondary research entailed a rigorous review of regulatory guidance documents, clinical practice recommendations, peer-reviewed literature on assay performance and utility, and corporate disclosures that elucidate strategic priorities and product capabilities. Data synthesis prioritized high-quality clinical validation studies and real-world evidence where available. All findings were cross-validated through triangulation to reconcile differing perspectives and to ensure that conclusions reflect consistent signals rather than isolated observations.

Where appropriate, analytical safeguards were applied to account for variability in care settings and regional policy environments. Methodological limitations were explicitly noted, particularly where evidence remains nascent or practice patterns are rapidly evolving. The research adhered to ethical standards for expert engagement and data handling, ensuring confidentiality and the integrity of qualitative insights.

A concise synthesis of how technological advances and strategic imperatives must be aligned to translate genomic testing into durable clinical and commercial impact

The convergence of advanced sequencing technologies, liquid biopsy innovations, and digital interpretation tools has irreversibly altered the clinical landscape for lung cancer genomic testing. These developments present both opportunities and challenges: opportunities to enable more precise treatment selection, to support adaptive clinical trials, and to deliver longitudinal monitoring with minimally invasive tests; and challenges in supply-chain management, evidence generation, and payer engagement that require strategic foresight. Decision-makers must therefore adopt an integrated view that aligns technological investment, clinical validation, and commercial pathways.

Effective responses will blend operational resilience with evidence-led commercialization. By diversifying supply sources, investing in compact and cost-efficient assays, and demonstrating clinical and economic value through robust studies, stakeholders can reduce exposure to policy and market shocks while accelerating adoption. At the same time, regionally nuanced strategies that respect local regulatory norms and healthcare infrastructures will be essential for converting global potential into sustainable clinical impact. In sum, the era of precision oncology in lung cancer depends on harmonized action across industry, clinical, and regulatory stakeholders to translate technical capability into improved patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of liquid biopsy assays for early detection of actionable lung cancer mutations using blood samples
  • 5.2. Integration of AI-driven bioinformatics platforms for rapid analysis of complex genomic profiles in NSCLC patients
  • 5.3. Adoption of comprehensive next generation sequencing panels to identify rare driver mutations and resistance mechanisms
  • 5.4. Growth of companion diagnostic approvals for targeted therapies in ALK, ROS1, EGFR mutated non small cell lung cancer
  • 5.5. Expansion of decentralized genomic testing services to improve accessibility in remote and underserved patient populations
  • 5.6. Implementation of reimbursement frameworks and value-based pricing models for advanced lung cancer genomic tests

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Lung Cancer Genomic Testing Market, by Technology

  • 8.1. Fluorescence In Situ Hybridization
  • 8.2. Microarray
  • 8.3. Next Generation Sequencing
    • 8.3.1. Targeted Sequencing
    • 8.3.2. Whole Exome Sequencing
    • 8.3.3. Whole Genome Sequencing
  • 8.4. Real Time Polymerase Chain Reaction
  • 8.5. Sanger Sequencing

9. Lung Cancer Genomic Testing Market, by Test Type

  • 9.1. Liquid Biopsy
    • 9.1.1. Circulating Tumor Cells
    • 9.1.2. Circulating Tumor Dna
  • 9.2. Tissue Biopsy
    • 9.2.1. Fine Needle Aspiration
    • 9.2.2. Tissue Section

10. Lung Cancer Genomic Testing Market, by Application

  • 10.1. Companion Diagnostics
  • 10.2. Predictive Testing
  • 10.3. Prognostic Testing
  • 10.4. Treatment Monitoring

11. Lung Cancer Genomic Testing Market, by End User

  • 11.1. Academic And Research Institutes
  • 11.2. Hospitals And Diagnostic Laboratories
  • 11.3. Pharmaceutical And Biotechnology Companies

12. Lung Cancer Genomic Testing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Lung Cancer Genomic Testing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Lung Cancer Genomic Testing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Illumina, Inc.
    • 15.3.2. Thermo Fisher Scientific Inc.
    • 15.3.3. F. Hoffmann-La Roche AG
    • 15.3.4. QIAGEN N.V.
    • 15.3.5. Guardant Health, Inc.
    • 15.3.6. Myriad Genetics, Inc.
    • 15.3.7. Natera, Inc.
    • 15.3.8. BioMerieux S.A.
    • 15.3.9. NeoGenomics Laboratories, Inc.
    • 15.3.10. Foundation Medicine, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. LUNG CANCER GENOMIC TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. LUNG CANCER GENOMIC TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. LUNG CANCER GENOMIC TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY MICROARRAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY MICROARRAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR DNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR DNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR DNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR DNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR DNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR DNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE SECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE SECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE SECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE SECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE SECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE SECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PREDICTIVE TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PREDICTIVE TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PREDICTIVE TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PREDICTIVE TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PREDICTIVE TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PREDICTIVE TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PROGNOSTIC TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PROGNOSTIC TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PROGNOSTIC TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PROGNOSTIC TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PROGNOSTIC TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PROGNOSTIC TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TREATMENT MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TREATMENT MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TREATMENT MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TREATMENT MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TREATMENT MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TREATMENT MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 230. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 232. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 236. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 238. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 246. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 247. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 248. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 249. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 252. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 253. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 254. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 280. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 281. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 282. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 283. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 286. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 287. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 288. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 289. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 290. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 291. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. GCC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. GCC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. GCC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEC